Literature DB >> 32092405

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy.

Xuanyan Cai1, Jiajia Wang1, Jincheng Wang1, Qian Zhou2, Bo Yang1, Qiaojun He3, Qinjie Weng4.   

Abstract

Liver fibrosis is a dynamic wound-healing process characterized by the net accumulation of extracellular matrix. There is no efficient antifibrotic therapy other than liver transplantation to date. Activated hepatic stellate cells (HSCs) are the major cellular source of matrix-producing myofibroblasts, playing a central role in the initiation and progression of liver fibrosis. Paracrine signals from resident and inflammatory cells such as hepatocytes, liver sinusoidal endothelial cells, hepatic macrophages, natural killer/natural killer T cells, biliary epithelial cells, hepatic progenitor cells, and platelets can directly or indirectly regulate HSC differentiation and activation. Intercellular crosstalk between HSCs and those "responded" cells has been a critical event involved in HSC activation and fibrogenesis. This review summarizes recent advancement regarding intercellular communication between HSCs and other "responded cells" during liver fibrosis and experimental models of intercellular crosstalk systems, and provides novel ideas for potential antifibrotic therapeutic strategy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antifibrotic therapy; Hepatic stellate cells; Intercellular crosstalk; Liver fibrosis

Year:  2020        PMID: 32092405     DOI: 10.1016/j.phrs.2020.104720

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  23 in total

Review 1.  Stem Cell-based Therapy Strategy for Hepatic Fibrosis by Targeting Intrahepatic Cells.

Authors:  Yaxin Deng; Bin Xia; Zhongmin Chen; Fuping Wang; Yonggang Lv; Guobao Chen
Journal:  Stem Cell Rev Rep       Date:  2021-10-19       Impact factor: 5.739

2.  Grevillea robusta Delayed the Progression of Experimentally Induced Hepatic Fibrosis and Cirrhosis in Wistar Rats by Attenuating the Expression of Smooth Muscle Actin, Collagen, and TGF-β.

Authors:  Saaid Hameed; Atta Ur Rehman; Shazma Massey; Nawazish-I-Husain Syed; Fareeha Anwar; Dildar Ahmed; Sarfraz Ahmad
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 3.  MicroRNA-34a: A Novel Therapeutic Target in Fibrosis.

Authors:  Min Zhao; Qin Qi; Shimin Liu; Rong Huang; Jiacheng Shen; Yi Zhu; Jing Chai; Handan Zheng; Huangan Wu; Huirong Liu
Journal:  Front Physiol       Date:  2022-06-20       Impact factor: 4.755

Review 4.  Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications.

Authors:  Jiulong Li; Chunying Chen; Tian Xia
Journal:  Adv Mater       Date:  2022-02-03       Impact factor: 32.086

5.  Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.

Authors:  Mengzhen Kuang; Hao Wu; Lan Hu; Xinying Guo; Daochuan He; Bo Liu; Mengqian Chen; Jie Gu; Jianxin Gu; Xiaoqing Zeng; Yuanyuan Ruan
Journal:  Glycoconj J       Date:  2021-02-20       Impact factor: 2.916

6.  Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II‑induced hepatic stellate cells activation.

Authors:  Shu Li; Wei Zhao; Zhimin Zhao; Binbin Cheng; Shuang Li; Chenghai Liu
Journal:  Mol Med Rep       Date:  2020-07-10       Impact factor: 2.952

7.  Complexation with Random Methyl-β-Cyclodextrin and (2-Hidroxypropyl)-β-Cyclodextrin Enhances In Vivo Anti-Fibrotic and Anti-Inflammatory Effects of Chrysin via the Inhibition of NF-κB and TGF-β1/Smad Signaling Pathways and Modulation of Hepatic Pro/Anti-Fibrotic miRNA.

Authors:  Alina Ciceu; Cornel Balta; Hidegard Herman; Sami Gharbia; Simona-Rebeca Ignat; Sorina Dinescu; Judit Váradi; Ferenc Fenyvesi; Szilvia Gyöngyösi; Anca Hermenean; Marieta Costache
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

Review 8.  Interaction of non‑parenchymal hepatocytes in the process of hepatic fibrosis (Review).

Authors:  Qi-Ni Cheng; Xue Yang; Jiang-Feng Wu; Wen-Bing Ai; Yi-Ran Ni
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

9.  Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.

Authors:  Siliang Wang; Cheng Tang; Heng Zhao; Peiliang Shen; Chao Lin; Yun Zhu; Dan Han
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 10.  Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.

Authors:  Haiou Li; Yunjiao Zhou; Haizhou Wang; Meng Zhang; Peishan Qiu; Mengna Zhang; Ruike Zhang; Qiu Zhao; Jing Liu
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.